Skip to main
CLDX
CLDX logo

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics Inc. demonstrates a robust financial position, ending the year with $725.3 million in cash, which is projected to support operations through 2027. The significant clinical advancements of barzolvolimab have resulted in up to 82% of patients with chronic spontaneous urticaria experiencing well-controlled conditions, alongside enhanced quality of life metrics. Additionally, the potential for barzolvolimab to achieve meaningful improvements in dysphagia could position it strongly against competitors, underscoring the company's innovative edge in the immunotherapy landscape.

Bears say

Celldex Therapeutics faces substantial risks related to the execution of its drug development and commercialization strategy, as failure in clinical trials could result in the rejection of regulatory approvals and diminish market potential. The company's reliance on securing adequate funding to advance its therapeutics through development is also a pressing concern, with the possibility of unsuccessful trials significantly impeding financial stability. Furthermore, although Celldex possesses a differentiated platform, competitive pressures may limit the adoption of its products, adding to the uncertainty surrounding the company's future prospects.

Celldex Therapeutics (CLDX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 17 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.